-$0.95 Earnings Per Share Expected for AnaptysBio, Inc. (NASDAQ:ANAB) This Quarter

Wall Street analysts expect AnaptysBio, Inc. (NASDAQ:ANABGet Rating) to report earnings per share (EPS) of ($0.95) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for AnaptysBio’s earnings. The lowest EPS estimate is ($1.17) and the highest is ($0.59). AnaptysBio reported earnings of ($0.02) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 4,650%. The business is scheduled to report its next earnings report on Monday, January 1st.

Zacks’ EPS averages are an average based on a survey of analysts that cover AnaptysBio.

AnaptysBio (NASDAQ:ANABGet Rating) last announced its quarterly earnings data on Wednesday, May 4th. The biotechnology company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.32). AnaptysBio had a negative net margin of 143.46% and a negative return on equity of 20.44%.

A number of analysts recently issued reports on ANAB shares. Zacks Investment Research upgraded AnaptysBio from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 17th. Guggenheim downgraded shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Tuesday, March 22nd. HC Wainwright raised their target price on shares of AnaptysBio from $43.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, March 7th. StockNews.com downgraded shares of AnaptysBio from a “hold” rating to a “sell” rating in a research note on Tuesday, April 26th. Finally, Wedbush reaffirmed a “neutral” rating on shares of AnaptysBio in a research report on Monday, March 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, AnaptysBio has a consensus rating of “Hold” and a consensus target price of $40.00.

AnaptysBio stock traded down $0.34 during mid-day trading on Friday, reaching $19.64. 2,422 shares of the company’s stock were exchanged, compared to its average volume of 249,269. The firm has a market capitalization of $553.57 million, a PE ratio of -7.27 and a beta of 0.17. The business’s fifty day simple moving average is $23.57 and its 200 day simple moving average is $29.10. AnaptysBio has a one year low of $19.51 and a one year high of $37.89.

In related news, major shareholder Ecor1 Capital, Llc bought 668,237 shares of the stock in a transaction that occurred on Thursday, May 5th. The shares were bought at an average cost of $21.63 per share, for a total transaction of $14,453,966.31. Following the completion of the transaction, the insider now owns 7,521,024 shares of the company’s stock, valued at $162,679,749.12. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 34.90% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its holdings in shares of AnaptysBio by 1.0% in the third quarter. BlackRock Inc. now owns 1,871,177 shares of the biotechnology company’s stock worth $50,746,000 after purchasing an additional 19,273 shares during the last quarter. State Street Corp increased its holdings in shares of AnaptysBio by 9.8% in the first quarter. State Street Corp now owns 958,095 shares of the biotechnology company’s stock worth $23,703,000 after purchasing an additional 85,786 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new position in AnaptysBio in the first quarter worth about $22,259,000. Dimensional Fund Advisors LP grew its position in AnaptysBio by 11.0% in the first quarter. Dimensional Fund Advisors LP now owns 891,851 shares of the biotechnology company’s stock worth $22,064,000 after acquiring an additional 88,457 shares in the last quarter. Finally, Woodline Partners LP grew its position in AnaptysBio by 36.7% in the first quarter. Woodline Partners LP now owns 833,927 shares of the biotechnology company’s stock worth $20,631,000 after acquiring an additional 223,946 shares in the last quarter.

About AnaptysBio (Get Rating)

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

Featured Articles

Get a free copy of the Zacks research report on AnaptysBio (ANAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.